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Randomized Placebo-Controlled Clinical Trial of a Chewable
Formulation of Amlodipine for the Treatment of Hypertension in
Client-Owned Cats
M. Huhtinen, G. Derre, H.J. Renoldi, M. Rinkinen, K. Adler, J. Aspegren, C. Zemirline, and J. Elliott
Background: There is an unmet clinical need for a cat-specific formulation of amlodipine to treat hypertensive cats.
Objectives: To assess the efficacy of chewable amlodipine tablets in reducing systolic blood pressure (SBP) in cats diag-
nosed with systemic arterial hypertension.
Animals: Seventy-seven client-owned cats with systemic hypertension were included (median age 14 years).
Methods: The study was randomized, double-blinded, and placebo-controlled. Forty-two cats received 0.125–0.50 mg/kg
amlodipine once daily for 28 days; 35 cats received placebo. After 28 days all cats continued with amlodipine for 2–3 months
in an open-label phase. Blood pressure was measured using high definition oscillometry. A responder was defined as a cat
showing a decrease of SBP to <150 mmHg at 28 days or a decrease from baseline ≥15%.
Results: Sixty-one cats completed the study. The responder rate was 63% in amlodipine group and 18% in placebo
group. Cats receiving amlodipine were 7.9 (95% CI 2.6–24.1) times more likely to be classified as responders when compared
to those receiving placebo (P < .001). From a mean (SD) baseline value of 181 (12) mmHg, SBP decreased to 154 (17)
mmHg with amlodipine and to 170 (21) mmHg with placebo (P < .001). The voluntary acceptance rate of amlodipine for-
mulation was 73%.
Conclusions and Clinical Importance: The chewable amlodipine tablet effectively reduced SBP compared with placebo in
hypertensive cats, and was well-tolerated. It can be used concomitantly with angiotensin-converting enzyme inhibitors and in
cats with chronic kidney disease.
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Cats usually develop secondary hypertension with anunderlying disease triggering increased blood pres-
sure (BP), although idiopathic hypertension, where no
underlying disease can be recognized, is seen in about 1
in 5 cases. Systemic hypertension in cats is most
commonly associated with acute or chronic kidney dis-
ease (CKD). Other conditions associated with the devel-
opment of secondary hypertension in cats include
hyperthyroidism, diabetes mellitus (DM), primary hyp-
eraldosteronism, and pheochromocytoma.1 Chronically
sustained increases in BP cause injury to various tissues,
mainly to kidneys, eyes, brain, and heart. This is com-
monly referred to as target organ damage (TOD).
According to the guidelines of the American College
of Veterinary Internal Medicine (ACVIM) Hypertension
Consensus Panel,1 hypertension is categorized according
to its risk of TOD: minimal risk (<150/95 mmHg), mild
risk (150–159/95–99 mmHg), moderate risk (160–179/
100–119 mmHg), and severe risk (>180/120 mmHg).
The goal of antihypertensive treatment is to maxi-
mally decrease the risk of TOD, which is achieved with
persistent BP reduction to values <150/95 mmHg. Cur-
rently, no drugs are approved for treatment of hyper-
tension in cats, but calcium channel blockers (CCB)
and angiotensin converting enzyme (ACE) inhibitors
are the most widely used antihypertensive agents in
practice.1
Amlodipine has been considered the treatment of
choice for hypertension in cats for more than a decade.
Amlodipine at a dose of 0.125–0.25 mg/kg once daily has
been shown to significantly decrease BP in spontaneously
hypertensive cats in several clinical trials.2–6 According to
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the ACVIM consensus statement on hypertension,1 stan-
dard veterinary textbooks, and other publications, CCBs
are the first choice for antihypertensive treatment in cats.
There is, however, no amlodipine product approved
for veterinary use for treatment of hypertension in cats;
therefore amlodipine approved for human use has been
used off-label in veterinary medicine. The product
approved for human use has certain disadvantages such
as difficult dosing because of high amlodipine concen-
tration and challenging administration because of lack
of palatable formulation. Thus, veterinary profession
lacks an approved medication effective in majority of
cases for feline hypertension.
The present study was undertaken to determine the
efficacy of chewable amlodipine tablets in cats diag-
nosed with systemic arterial hypertension. The formula-
tion used in this study has been shown to have similar
in vitro dissolution profile (immediate release tablet) to
that of the human formulation.
Materials and Methods
Study Design
The randomized, multicenter, double-blinded, placebo-con-
trolled, parallel group study was conducted at 20 private veteri-
nary clinics in 3 European countries (Finland, France, and
Germany). This study was conducted in accordance with the
principles of Good Clinical Practice.7 Informed consent was
obtained from each animal owner prior to enrollment. The wel-
fare, treatment, and care of study animals at study sites were
ensured by veterinary supervision. Permission to conduct the
study was received from each National Regulatory Agency prior
to commencement.
Study Animals
Cats included in the study were identified by the participating
veterinarians in the course of their routine clinical practice. Veteri-
nary practices were encouraged to screen cats at risk (old cats,
including those with CKD or other diseases related to hyperten-
sion). To be eligible for the study, cats had to weigh between 2.5
and 10.0 kg, and have a systolic blood pressure (SBP) ≥165 mmHg
on 2 separate visits within 2 weeks, to rule out white coat hyper-
tension. If the cat had a primary disease associated with hyperten-
sion (e.g. CKD, hyperthyroidism, primary hyperaldosteronism,
DM, or pheochromocytoma), the primary disease had to be stable
with no need for immediate initiation of other medication or dose
adjustment of current medication.
Cats were excluded from study if they met any of the following
criteria: use of systemic treatment with CCBs, vasodilators, alpha-
1 adrenergic antagonists, angiotensin receptor blockers, beta-
blockers, aldosterone antagonists within 30 days of screening; use
of long-acting glucocorticoids or continuous use of short-acting
glucocorticoids within 3 months of screening, initiation or change
in dosing of methimazole, carbimazole, phenylpropalamine, non-
steroidal anti-inflammatory drugs, diuretics, short-acting systemic
glucocorticoids, or any other medication for primary disease
within 14 days of screening; starting on ACE inhibitors or insulin
treatment for DM or a change in dosing of existing ACE inhibi-
tors or insulin or renal diet within 30 days of screening and; pres-
ence of ocular or neurological signs, which were deemed to be
caused by hypertension and requiring immediate medical treat-
ment. Cats were also excluded if SBP >200 mmHg was recorded,
unless the investigator estimated that the cat could be enrolled in
the study. Other reasons for exclusion were presence of clinically
relevant liver failure or impaired hepatic function and unstable
CKD that was expected to worsen markedly during the study.
The dose of amlodipine was determined from data found in lit-
erature. In previous studies, most cats received an initial single
dose of 0.625 mg amlodipine daily. This dosage regimen was cho-
sen mainly for practical reasons as this corresponds to 1/8 of the
5 mg tablet registered for human use.
The amlodipine product used in this study was a chewable
chicken flavored tablet designed for cats. Placebo tablets were
equal in size and shape, contained the same excipients but no
active ingredient.
The overall study design and plan is presented in Figure 1. The
study consisted of 2 phases with differing designs. Phase 1 (blinded
efficacy period, 28  3 days) was double-blind. Cats were random-
ized to receive amlodipine 0.125 mg/kg (range 0.125–0.25 mg/kg)
or placebo given PO by the owner once daily at home. If after
2 weeks SBP was ≥150 mmHg or had decreased <15% from base-
line value, the dose was doubled.
Phase 2 (safety period) was an open-label safety follow-up
with all cats receiving amlodipine. The cats that had received
amlodipine during phase 1 continued their medication for
2 months, while all placebo cats started receiving amlodipine
0.125 mg/kg (range 0.125–0.25 mg/kg) for 3 months. The dose
Fig 1. Study design.
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was doubled after 2 weeks if SBP did not meet the same criteria
as in phase 1.
Blood Pressure Measurements
Blood pressure was measured in accordance with the ACVIM
guidelines1 using a high definition oscillometry (HDO) device.a
Measurements were made at each visit before performing any
other examination or manipulation. Cats were allowed to acclima-
tize in a quiet room 5–10 minutes before measurement, if needed.
All measurements were obtained using the same cuff size, place
(tail), and body position (standing or lying on the owner’s lap).
The cuff was placed at the level of heart, regardless of the position
of cat. Measurement quality was visually verified from computer
trace and recorded. The average of 5 consistent measurements,
within 15 mmHg of each other, was used. All measurements were
verified by the same person.
All investigators were trained in the measurement technique
and use of the HDO device.
Other Variables
Quality of Life (QoL) was evaluated on a 4-point scale
(Table 1). The questionnaire consisted of 4 items: appetite; drink-
ing and urinating; mobility and owner interactions; and self-
grooming habits. Additionally, owner evaluated overall improve-
ment in the cat’s condition.
Palatability was scored on a 3-point scale: tablet taken sponta-
neously from hand or from empty bowl (1); tablet taken with food
from bowl or administered within palatable food (2); tablet admin-
istered directly into mouth (3). Scores 1 and 2 were considered as
palatable, while score 3 was considered not palatable. The investi-
gator evaluated palatability and possible changes based on owner’s
interview and diary data.
Safety was assessed by recording adverse events (AE), physical
examination findings, cardiorespiratory status, and laboratory
variables. An AE was any observation in animals that was
unfavorable and unintended and occurred after the use of the
investigational veterinary product, whether considered to be prod-
uct related.
Statistical Methods
The target number of cats in the study was 72 with group sizes
of 36 giving 90% power to detect superiority, assuming 70% and
30% response rates in amlodipine and placebo groups respectively.
Block randomization was used with different block size for cats
with CKD than for cats without CKD.
Comparison between groups was made using Wilcoxon rank
sum test for numeric data and Fisher’s exact test for categorical
data. The change from baseline SBP at the end of blinded efficacy
period (Day 28) was evaluated as a dichotomous variable, where a
responder was defined as decrease of SBP to <150 mmHg or
decrease from baseline of at least 15%. This was the primary effi-
cacy variable and factors influencing its attainment were analyzed
with a logistic regression model, where baseline SBP, CKD (pres-
ent or absent), and concomitant ACE inhibitor use (yes or no)
were used as covariates.
A repeated measures analysis of covariance model was used to
analyze absolute changes in SBP. The model included the same
fixed effects as logistic regression model together with visit as a
repeated factor and the treatment-by-visit interaction. All other
variables were tabulated with descriptive statistics. A P-value of
<.05 was taken to indicate statistical significance.
Results
A total of 128 cats were assessed for eligibility for the
study; 77 cats were enrolled. Forty-two cats were ran-
domized to receive amlodipine and 35 cats received pla-
cebo. Sixteen cats discontinued the study, 3 of which
discontinued during the blinded efficacy period. The
most common reason for discontinuation was an AE.
Thus, 61 cats completed the study.
No clinically or statistically significant differences in
demographic and baseline characteristics were found
between the 2 groups at entry to the study (Table 2).
The protocol allowed the use of ACE inhibitors; 12
cats continued to use an ACE inhibitor (9 benazepril, 2
imidapril, and 1 ramipril) during the study.
Systolic Blood Pressure
Responder rate at the end of the blinded efficacy per-
iod (Day 28) was significantly higher (adjusted odds
ratio 7.9; 95% CI 2.6–24.1) in the amlodipine group
(63%) than in the placebo group (18%). Individual
responses for each cat are shown in Figure 2.
In the first 14 days of treatment, the median dose
of amlodipine was 0.179 (range 0.125–0.25) mg/kg.
On Day 14, 19 of 41 (46%) cats allocated to receive
amlodipine met criteria of responding to treatment
(SBP <150 mmHg or a reduction in SBP of ≥15%)
and 22 (54%) did not. This contrasted with 7 of 35
(20%) cats from placebo group that responded and
28 (80%) that did not. For the nonresponding cats,
median dose of amlodipine was increased to 0.379
(range 0.25–0.50) mg/kg and by Day 28, 25 of 40
cats (63%) remaining in study were responders. This
contrasted with 6 of 34 cats receiving placebo (18%)
that were responders. Cats receiving amlodipine were
Table 1. Numerical rating scale for the assessment of
quality of life.
Score Description
Appetite
0 Excellent, always consumes whole meal
1 Good, consumes most of the meal
2 Moderate, consumes some but usually leaves some
3 Poor, consumes little and leaves most of the meal
Drinking and urinating
0 Normal
1 Occasionally and/or mildly increased drinking/urinating
2 Moderate, consumes more water and urinates more
3 Consumes water and urinates in excess
Mobility and owner interactions
0 Excellent; moves around, plays and interacts with joy/ as
a healthy cat of the breed in question
1 Good; moves around, plays and interacts with joy but
may occasionally seem tired
2 Moderate; reluctant to move around, play or interact
3 Poor; refuses to move around, play or interact
Self-grooming habits
0 Grooms itself normally
1 Grooms somewhat less often
2 Grooms markedly less often
3 Has stopped grooming
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7.9 (95% CI 2.6–24.1) times more likely to be
responders than cats receiving placebo, which was
statistically significant (P < .001). Logistic regression
analysis showed that treatment (amlodipine versus
placebo) was the only significant factor. An unad-
justed logistic regression analysis confirmed results of
the adjusted model.
Decrease in mean SBP was significantly (P < .001)
greater in the amlodipine group than in the placebo
group (Fig 3). A 10 mmHg reduction in SBP was seen
in the placebo group which stabilized within 14 days,
whereas amlodipine treatment led to a 28 mmHg reduc-
tion in SBP after 28 days.
In subgroup analysis by disease etiology, a similar pro-
portion of cats with CKD (71.4%), hyperthyroidism
(75%), and other diseases (75%) responded to amlodipine
treatment by Day 28, whereas only 30% of cats with idio-
pathic hypertension were responders.
Other Efficacy Variables
Palatability (i.e. voluntary acceptance of the tablet
with or without food) during the first 4 weeks was 80%
with amlodipine and 59% with placebo. Palatability
was stable throughout the study in cats that started
with amlodipine but increased somewhat in placebo cats
when they started amlodipine treatment. Overall palat-
ability with amlodipine during the 3-month treatment
period was 73%. There were no statistical differences
between the groups.
The QoL score improved somewhat during the study
(from 2.8 to 2.4 with amlodipine, and from 3.1 to 2.4
Table 2. Demographic and baseline characteristics of cats enrolled in the study.
Variables
Amlodipine
N = 42
Placebo
N = 35
Total
N = 77 P-value*
Systolic blood pressure 177 (165–220) 177 (166–204) 177 (165–220) .45
Age (years) 14.0 (7–20) 14.0 (9–18) 14.0 (7–20) .31
Weight (kg) 3.7 (2.5–7.5) 4.2 (2.5–6.8) 4.0 (2.5–7.5) .17
Breed
Domestic 16 (38.1) 14 (40.0) 30 (39.0) .13
European 17 (40.5) 14 (40.0) 31 (40.3)
Persian 5 (11.9) – 5 (6.5)
Other 4 (9.5) 7 (20.0) 11 (14.2)
Sex (all neutered)
Female 19 (45.2) 17 (48.6) 36 (46.8) .82
Male 23 (54.8) 18 (51.4) 41 (53.2)
S-creatinine (mg/dL) 1.6 (0.6–4.7) 1.8 (0.6–4.4) 1.7 (0.6–4.7) .74
U-specific gravity 1.02 (1.01–1.07) 1.03 (1.01–1.06) 1.03 (1.01–1.07) .81
U-protein/creatinine ratio 0.2 (0.1–1.9) 0.2 (0.1–0.8) 0.2 (0.1–1.9) .15
Primary disease
Renal disease 14 (33.3) 12 (34.3) 26 (33.8) .63
Hyperthyroidism 9 (21.4) 10 (28.6) 19 (24.7)
Idiopathic hypertension 11 (26.2) 10 (28.6) 21 (27.3)
Other 8 (19.0) 3 (8.6) 11 (14.3)
Angiotensin converting enzyme inhibitors
Yes 7 (16.7) 5 (14.3) 12 (15.6) >.99
No 35 (83.3) 30 (85.7) 65 (84.4)
Data are median (range) or number (%).
*P-value for comparison of groups using Wilcoxon rank sum test for numeric data and Fisher’s exact test for categorical data.
A B
Fig 2. Individual responses (responder or nonresponder) for each cat after blinded efficacy period (Day 28).
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with placebo), but there were no statistical differences
in QoL between the groups.
According to owner’s evaluation, a higher proportion
of cats seemed to feel better in the amlodipine group
than in the placebo group (35% versus 15%, respec-
tively, P = .066).
Adverse Events
There were no differences in frequency of AEs
between the amlodipine and placebo groups during 28-
day blinded efficacy period (Table 3). AEs were fol-
lowed for the whole 3–4 month study period during
which the most common AEs were emesis (13%), anor-
exia/appetite disorder (8%), hyperthyroidism (7%),
dehydration and lethargy (5%).
Laboratory Variables
There were generally few appreciable changes in labo-
ratory values. Creatinine remained essentially
unchanged during the study in the amlodipine group
(decreased by 0.02 mg/dL [0.26], P = .77), while it
increased somewhat in the placebo group (by 0.18 mg/
dL [0.54], P = .012). The median baseline values were
fairly high (about 1.7 mg/dL in both groups) and an
increase >25% from baseline to Day 28 was observed in
10% of 40 amlodipine cats and in 15% of 34 placebo
cats. At the end of study, 9% of 67 amlodipine treated
cats had creatinine increases >25%. There were no
appreciable changes in urea in either group. Potassium
decreased somewhat in the amlodipine group, from 4.3
(0.50) to 4.2 (0.44) mmol/L (P = .082), and
increased in the placebo group, from 4.4 (0.59) to 4.6
(0.68) mmol/L (P = .020), but both of these changes
were not deemed clinically relevant. No notable change
was seen in urine protein to creatinine ratio.
Discussion
The present study describes the effects of amlodipine
in hypertensive client-owned cats compared to placebo.
It confirms findings of the first placebo-controlled study
which involved just 9 cats3 and other uncontrolled stud-
ies.2,5 It increases our confidence because of the fact
that changes induced by amlodipine were compared to
placebo in a large cohort of cats seen in primary care
practices and improves understanding of the dose
required to produce a clinically relevant reduction in
arterial BP. Precision in dosing amlodipine in the pres-
ent study was facilitated by a cat-specific formulation of
amlodipine and a tablet size that facilitated dosing
between 0.125 and 0.5 mg/kg body weight.
The design of the present study demonstrates that
when BP of 34 cats is measured repeatedly, the adminis-
tration of a placebo tablet led to an apparent reduction
of about 10 mmHg (5% reduction from baseline) after
14 days. No further reduction was seen after further
14 days in the placebo group suggesting this decrease in
BP might be accounted by a training effect although
other explanations are possible. This contrasted with
change in SBP seen in group of 40 cats receiving amlod-
ipine which decreased by more than twice the reduction
seen in the placebo group. Doubling the amlodipine
dose resulted in further significant reduction in SBP
over next 14 days increasing the difference between the
2 groups after 28 days of treatment. The effect of am-
lodipine was further demonstrated in placebo group
after they were switched to receive amlodipine. Their
SBP reduced to very similar levels to those seen in am-
lodipine treated cats by Day 42 of the study.
In addition to having the gold standard design of a
randomized, controlled, double-blinded clinical trial, the
present study had a number of other strengths which
Fig 3. Mean (SD) changes from baseline in systolic blood pres-
sure during the blinded efficacy period.
Table 3. Most common (n > 1) AEs during blinded efficacy period (up to 28 days).
System Organ Class
Amlodipine Placebo
P-value*
N = 42 N = 35
f n % f n %
Any event 23 12 28.6 17 10 28.6 >.99
Digestive tract disorders (ascites, diarrhea, emesis, gingival disorder, tooth disorder) 6 5 11.9 5 4 11.4 >.99
Renal and urinary disorders (cystitis, nephritis, renal insufficiency, urine abnormalities) 4 4 9.5 4 4 11.4 >.99
Systemic disorders (abscess, anorexia, death, lethargy, trauma, weight loss) 2 2 4.8 4 2 5.7 >.99
Endocrine system disorders (hyperthyroidism, unspecified thyroid gland disorder) 4 3 7.1 1 1 2.9 .62
f, number of events; n, number of subjects; %, % of subjects.
*P-value from comparison of subject counts using Fisher’s exact test.
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set it apart from previous published studies. Firstly, pri-
mary efficacy measure was defined a priori as a reduc-
tion in SBP to below 150 mmHg or a decrease from
baseline pressure of more than 15%. Furthermore,
number of cats recruited was determined by a power
calculation which assumed that 70% of amlodipine
treated and 30% of placebo treated cats would attain
this primary efficacy endpoint. The power calculation
showed that 72 cats would need to be recruited if these
assumptions were correct, in order to determine whether
amlodipine was superior to placebo in achieving this
endpoint. In the 2 placebo-controlled studies in the
published literature,3,8 one was very much a pilot study
involving just 9 client-owned cats3 and other was an
experimental model study where hypertension was
induced by subtotal nephrectomy.8 Neither of these
studies had determined a target BP reduction a priori
and no power calculations are mentioned in these
papers.
Another factor that distinguishes the present study is
its multicentric design. It shows that the results are
applicable across a range of different clinics in 3 Euro-
pean countries. The fact that the study was well-
designed with clear inclusion/exclusion criteria was
essential for it to work as a multicenter study. Further-
more, it was essential to standardize the method of BP
measurement and ensure all personnel measuring BP
were well-trained in the selected method. None of the
commonly used indirect BP measurement techniques
used in clinical practice performs sufficiently well that
they would be approved by the Association of Medical
Instruments as being valid. High definition oscillometry
was selected for the present study and recent data9 sug-
gests that this method compares favorably with direct
telemetry measurements made in young healthy cats. It
has the advantage of providing a digital output that can
be stored and examined after the measurement session
by an expert to quality control the values taken in
clinic. Thus, the method of BP measurement selected
for this trial minimized intraoperator variability by
standardization through training and additional quality
control measures.
The primary efficacy endpoint used in the present
study was based on expert opinion of the risk of TOD
resulting from persistently elevated BP. A reduction of
SBP below 150 mmHg would decrease the risk of TOD
from moderate to negligible according to the ACVIM
consensus statement on hypertension.1 Cats entering the
study with a baseline SBP between 165 and 176 mmHg,
would respond if their SBP was reduced below
150 mmHg (15% of the baseline SBP). Responders with
starting SBP between 177 and 187 mmHg would notice
a reduction in SBP below 160 mmHg (going from mod-
erate or severe risk to mild risk) and those between 188
and 211 mmHg baseline SBP, would be taken from
severe risk to moderate risk (160–180 mmHg) of TOD.
Thus, achievement of primary efficacy endpoint, by con-
sensus, should lead to protection of hypertensive cats
against TOD.
Two-thirds of the recruited cats (63%) randomized to
receive amlodipine were responders whereas just 1 in 6
cats (18%) apparently responded to placebo. The rea-
son why administration of placebo led to a reduction in
BP relative to baseline is unclear. One possible explana-
tion is that this represented a training effect in response
to repeated BP measurement sessions over a period of
3–4 months. Classification of a cat as a responder was
not influenced by factors other than amlodipine treat-
ment (e.g. baseline SBP, concomitant ACE inhibitor
treatment, underlying disease). In previously published
studies, administration of amlodipine has been associ-
ated with reductions in SBP of over 40 mmHg.2,3,6 The
most likely reasons for larger reduction in BP achieved
in previous studies, is that a higher proportion of cats
enrolled in these studies had baseline SBP values above
200 mmHg. Although practitioners could use their dis-
cretion in enrolling cats with such high SBP in the pres-
ent study, it seems likely that as this was a randomized
placebo-controlled trial, the veterinarians and owners
were reluctant to enroll cats with such high SBP partic-
ularly where there was evidence of TOD (usually hyper-
tensive retinopathy). Indeed, in the present study,
secondary analysis showed that the absolute magnitude
of reduction in SBP was influenced by baseline SBP
value as well as whether the cat received amlodipine,
supporting the conclusion that smaller reduction in SBP
seen in the present study is explained by the relatively
lower baseline SBP of the cats enrolled.
Nevertheless, the population of cats enrolled in the
present study appears to be typical of those seen in clin-
ical practice that are diagnosed with systemic arterial
hypertension.2,5,10–13 They were typical in terms of age
(median age 14 years), sex (equal numbers of neutered
males and females), breed (majority of cats being non-
pedigree) and underlying disease (CKD International
Renal Interest Society (IRIS) stage 2 and 3, hyperthy-
roidism and idiopathic making up the majority of the
diagnoses). The major difference from previous studies
was the relatively low prevalence of hypertensive reti-
nopathy seen, again possibly explained by the reluc-
tance of veterinarians and owners to enroll cats into a
placebo-controlled study when there is clear evidence of
TOD. The block randomization procedure produced 2
groups well-matched in terms of all of these factors as
well as the baseline SBP. The post-treatment SBP
achieved with amlodipine treatment in the present study
was similar to that seen in other studies (median value
of 150 mmHg). As discussed above, reduction in SBP
achieved relative to that seen in the placebo was clini-
cally significant and highly likely to be protective in the
cats responding. Only a small minority of cats (16%)
were taking ACE inhibitors and this concomitant treat-
ment did not influence whether a cat was classified as a
responder or not.
Looking at SBP and responder rates by disease etiol-
ogy, cats with idiopathic hypertension showed higher
proportion of nonresponders compared to cats with
other underlying diseases like CKD or hyperthyroidism.
Present medical history, AEs during the study or age of
cats gave no obvious explanation for these cats not
responding to treatment. However, the conclusion
that cats with idiopathic hypertension react less to
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amlodipine than cats with other diseases cannot be
made because of small number of cases.
The factors that meant the minority (just over a
third) of cats being nonresponders to amlodipine
remain to be determined; possible factors including
poor compliance, individual (including genetic) varia-
tion in pharmacodynamics or pharmacokinetics of am-
lodipine or resistance of the underlying pathophysiology
of the hypertension to arterial vasodilators. In human
medicine, large studies of factors influencing response
of hypertensive patients to amlodipine have not identi-
fied genetic factors, either through a candidate gene
approach14 or genome wide association studies.14,15 In a
human clinical trial,15 low calcium, low cholesterol, and
low urinary sodium excretion were all associated with
more effective response of patients to the BP lowering
effect of amlodipine. In humans, amlodipine is a
CYP3A enzyme substrate and some studies have identi-
fied certain genotypes (e.g. CYP3A5*3/*3) to be associ-
ated with greater response to amlodipine but this is
highly dependent on the population studied and compli-
cated by the role of the CYP3A enzyme involved in cor-
tisol and corticosterone metabolism; and the
explanation of differences seen between different geno-
types of CYP3A may not necessarily relate to pharma-
cokinetics of amlodipine.14 It is clear that future
research should explore factors explaining the variation
in response of client-owned hypertensive cats to amlodi-
pine.
Nevertheless, the present study confirms amlodipine
as a highly efficacious antihypertensive agent. The AEs
seen in the present study were what might be expected
in elderly cats with multiple medical problems. They
were very similar in frequency and nature between am-
lodipine and placebo groups over the first 28 days of
study indicating that they were unlikely to be directly
related to amlodipine treatment itself.
The present study has confirmed the efficacy and
safety of amlodipine as a monotherapy for majority of
cats with hypertension. Cats given a placebo showed a
small reduction in BP with a small minority being clas-
sified as responders demonstrating the importance of
including a placebo when assessing antihypertensive
drug treatments in hypertensive cats.
Conclusion
The present study shows that amlodipine is superior
to placebo in treatment of client-owned cats with
hypertension. The chewable amlodipine formulation
effectively reduced SBP, had good palatability and was
well-tolerated. It can be used concomitantly with ACE
inhibitors and in cats with CKD.
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